High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma

Melanoma Research

Volumn 11, Issue 2, 2001, Pages 157-166

  Nikkola, J ^a   Vihinen, P ^a   Vlaykova, T ^a   Hahka Kemppinen, M ^a   Kahari V M ^a   Pyrhonen S ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Metastatic melanoma; MMP 1 expression; Therapy response

Indexed keywords

COLLAGENASE 3; INTERSTITIAL COLLAGENASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; AGED; COLLAGENASES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035038518     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200104000-00011     Document Type: Article

References (47)

1. Matrix metalloproteinases and their inhibitors in tumour growth and invasion
2. Matrix metalloproteinases: A review
3. Tumor cell interactions with the extracellular matrix during invasion and metastasis
4. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas
5. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage
6. Matrix metallo-proteinases in tumor invasion
7. Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis
8. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations
9. Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation
10. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck
11. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas
12. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor
13. Human collagenase-3 is expressed in malignant squamous epithelium of the skin
14. Expression of collagenase-3 (matrix metalloproteinase-13) in transitional cell carcinoma of the urinary bladder
15. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers
16. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
17. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer
18. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer
19. Expression of the MMP-1 in human pancreatic carcinoma: Relationship with prognostic factor
20. Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: Correlations with tumor invasion and metastasis
21. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value
22. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas
23. Matrix metalloproteinases in human melanoma cell lines and xenografts: Increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression
24. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - A new prognostic marker in uveal melanoma?
25. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin
26. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line
27. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells
28. Antimetastatic and antitumor effect of a recombinant human tissue inhibitor of metalloproteinases-2 in murine melanoma models
29. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma
30. MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma
31. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma
32. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma
33. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
34. Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy
35. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy
36. DNA flow cytometry and the outcome of chemoimmunotherapy in metastatic melanoma
37. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma
38. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy
39. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients
40. Changing views of the role of matrix metalloproteinases in metastasis
41. Modulation of type-IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type-IV collagenase
42. Collagenase immunolocalization studies of cutaneous secondary melanomas
43. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunochemical analysis of MIB-1 proliferative activity in melanocytic tumors
44. Serum matrix metalloproteinase-9: Tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma
45. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response
46. Matrix metalloproteinases expressed in squamous cell carcinoma of the oral cavity: Correlation with clinicopathologic features and neo-adjuvant chemotherapy response
47. Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy